% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Deugd:303196,
author = {R. d. Deugd and J. C. Riano and E. de Vries and A. F.
Cardona and J. Rodriguez and A. Fidalgo-Zapata and Y.
Sanchez and S. Sanchez and J. Olaya and D. de Leon and C. A.
Ossa and H. Reynales and P. Quintero and E. Vargas and U.
Hamann$^*$ and D. Torres},
title = {{E}stablishing the {F}irst {G}enetic {V}ariant {R}egistry
for {B}reast and {O}varian {C}ancer in {C}olombia:
{I}nsights and {I}mplications.},
journal = {Diseases},
volume = {13},
number = {7},
issn = {2079-9721},
address = {Basel},
publisher = {MDPI},
reportid = {DKFZ-2025-01547},
pages = {222},
year = {2025},
abstract = {Genetic insights from diverse populations are key to
advancing cancer detection, treatment, and prevention.
Unlike other Latin American countries, Colombia lacks a
centralized registry for germline and somatic mutations in
breast and ovarian cancer. This study describes the
country's first national variant registry, and the
occurrence of recurrent mutations and potential founder
effects in Colombia.To address this gap, we implemented the
first capturing protocol using the REDCap system. In a group
of 213 breast and/or ovarian cancer patients harboring
genetic mutations, we collected genetic, clinical, and
demographic data from 13 regional centers across Colombia.
Statistical analyses assessed variant distribution and
patient demographics.Among 229 identified variants (105
germline, 124 somatic), most were classified as pathogenic
or likely pathogenic $(72.4\%$ germline, $87\%$ somatic).
BRCA1 and BRCA2 accounted for the majority of recurrent
mutations. Germline recurrent variants (seen >3 times) were
recorded for BRCA1 $(77.7\%;$ 21/27) and BRCA2 $(22.3\%;$
6/27). Similarly, recurrent somatic variants were identified
for BRCA1 $(82.6\%;$ 38/46) and BRCA2 $(17.4\%;$ 8/46).
Notably, four recurrent variants were previously reported as
founder mutations: BRCA1 c.1674del $(14.3\%$ germline and
$23.7\%$ somatic), BRCA1 $c.3331_3334del$ $(33.3\%$ germline
and $52.6\%$ somatic), BRCA1 c.5123C>A $(52.4\%$ germline
and $23.7\%$ somatic), and BRCA2 $c.2808_2811del$ $(50\%$
germline and $50\%$ somatic). Most cases originated from the
Andean region, highlighting regional disparities.This
registry offers the first overview of genetic variants in
Colombian breast and ovarian cancer patients. Recurrent and
region-specific mutations highlight the need for
population-focused data to guide targeted screening and
personalized care strategies.},
keywords = {breast cancer (Other) / cancer registry (Other) /
cancer-associated genes (Other) / genetic variants (Other) /
ovarian cancer (Other) / precision medicine (Other)},
cin = {B072},
ddc = {610},
cid = {I:(DE-He78)B072-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40710012},
doi = {10.3390/diseases13070222},
url = {https://inrepo02.dkfz.de/record/303196},
}